In addition, given the complexity and the multicellular nature of the IPF lung explants, inhibiting PIM1 in this context may impinge on multiple pathways and cell types, thus reinforcing its antifibrotic activity; inhibiting NFATc1 alone may not be as effective. Here, PIM1 is linked to idiopathic pulmonary fibrosis.